What’s New — and
Where to Find Us
Conferences we’re attending, plus the latest announcements from the SplashBIO™ team.
Where to Find Us
Upcoming conferences where you can meet the SplashBIO™ team.
CTAD 2026 — Clinical Trials on Alzheimer’s Disease
Join us at CTAD to see how independent, centralized pre-screening reduces screen failures and accelerates enrollment.
Request a meetingNews & Press
Announcements, releases, and coverage.
SplashBio Launches, Aiming to Cut Alzheimer’s Trial Screen Failures With Biomarkers
Precision medicine reporter Jessica Kim Cohen spoke with founder and CEO Matt Teuteberg about how SplashBIO™ moves biomarker pre-screening earlier in the enrollment process, so fewer patients go through a full site screening only to find out they aren't eligible.
Read the article at GenomeWeb (subscription)SplashBIO™ Launches as an Independent Platform Company
SplashBIO™ announced its launch as an independent, biomarker-driven enrollment platform — spun out from Splash Clinical to bring validated blood biomarker pre-screening to the front of the clinical trial, reducing screen failures and accelerating enrollment.
Read the releaseSplashBIO™ Completes Its Scientific Advisory Board
SplashBIO™ announced a four-member Scientific Advisory Board spanning cognition science, biostatistics, bioethics and law, and clinical neurology — bringing deep Alzheimer’s research expertise to its enrollment platform.
Meet the boardBetter Trial Enrollment
Starts Earlier.
Let’s modernize clinical trial enrollment together and unlock a new era of efficiency.